Stockscreener 앱 받기
18.30
2.30%
0.4378
전일 마감가:
$17.86
열려 있는:
$17.96
하루 거래량:
521.89K
Relative Volume:
0.29
시가총액:
$1.60B
수익:
$203.45M
순이익/손실:
$-351.45M
주가수익비율:
-4.0482
EPS:
-4.52
순현금흐름:
$-369.41M
1주 성능:
-1.08%
1개월 성능:
+0.94%
6개월 성능:
+176.40%
1년 성능:
+223.36%
1일 변동 폭
$17.89
$18.64
1주일 범위
$16.86
$18.64
52주 변동 폭
$5.12
$20.33
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TVTX | 18.28 | 1.60B | 203.45M | -351.45M | -369.41M | -4.52 |
| VRTX | 448.77 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.78 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Oppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices
Travere: Q3 Earnings Snapshot - AOL
Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
3 Under-the-Radar Healthcare Companies - sharewise
3 Under-the-Radar Healthcare Companies to Watch - MarketBeat
Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat
TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India
Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP
Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga
Travere Therapeutics plans public stock offering - Investing.com India
Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan
Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):